Prostanoid Biosynthesis: AA Cascade and COX Enzymes
Prostanoid synthesis (eicosanoids from 20-carbon polyunsaturated FA; primary substrate: arachidonic acid (AA; C20:4 n-6; esterified in sn-2 position of membrane phospholipids)): liberation (cPLA2α (cytosolic phospholipase A2α; MAPK p38/ERK → Ser505 phosphorylation → membrane translocation; Ca2+-dependent; PC/PE→LPC/LPE + AA; MAFP-sensitive)) → COX enzymes (cyclooxygenase-1 (PTGS1; constitutive; gastric mucosa/platelets/kidney; gastroprotective PGE2 (EP3), PGI2, TXA2); cyclooxygenase-2 (PTGS2; inducible; NF-κB/AP-1 → COX-2 mRNA (NF-κB site −447 bp); IL-1β/TNF-α/LPS induced; peroxidase + dioxygenase activities: AA + 2O2 → PGG2 → PGH2)) → terminal synthases: PTGES1/2/3 → PGE2 (EP1 (Ca2+/IP3), EP2 (Gs/cAMP), EP3 (Gi/↓cAMP), EP4 (Gs/cAMP/β-arr))); TXAS → TXA2 (TP receptor; Gq/Ca2+ → platelet activation, vasoconstriction); PGIS → PGI2 (IP receptor; Gs/cAMP → vasodilation, anti-platelet); PGDS → PGD2 (DP1/DP2; DP2 = CRTH2 → Th2 eosinophil chemoattraction); 15-PGDH → PGE2 catabolism (15-keto-PGE2 → inactive).
Spirulina Mechanisms in Prostanoid Biology
COX-2/NF-κB Transcriptional Suppression
COX-2 (PTGS2; the dominant inflammatory prostanoid source; NF-κB-driven: p65/p50 binding to −447 bp κB site + AP-1 (c-Fos/c-Jun) at −59 bp TRE → synergistic COX-2 transcription; mRNA stabilised by HuR (ARE-binding; IL-1β → HuR cytoplasmic translocation → COX-2 mRNA half-life 2h → 12h); COX-2 protein: ~72 kDa; haem-containing dimer; COX-2 selective inhibitors: celecoxib (Vioxx class; COX-2 side-pocket Val523); NSAIDs: aspirin (irreversible Ser530 acetylation → AA → blocked; aspirin-COX-2 → 15R-HETE → 15-epi-lipoxin A4)) is suppressed by spirulina: (1) NF-κB/IKKβ (−30–45%) → COX-2 mRNA −30–45%; p65 nuclear occupancy at PTGS2 promoter −30–40% (ChIP data from LPS macrophage models); (2) AP-1 (phycocyanin → c-Jun N-terminal kinase JNK inhibition → c-Jun Ser63/73 phosphorylation −25–35% → AP-1 transactivation reduced); (3) mRNA stability: NF-κB → HuR nuclear retention (paradox: reduced HuR cytoplasmic → COX-2 mRNA destabilised → shorter half-life); (4) Nrf2 Nrf2-COX-2 crosstalk: Nrf2 → HO-1/CO → COX-2 haem degradation (minor; HO-1-CO modest COX-2 haem competition). Net: PGE2 −20–35%; TXA2 −15–25% (macrophage, synoviocyte, vascular SMC models).
cPLA2 Inhibition: Arachidonate Release Reduction
cPLA2α (MAPK Ser505 phosphorylation required for membrane translocation; Ca2+-dependent C2 domain; essential for AA release during inflammatory signalling; MAPK: ERK1/2 (growth factors) and p38 MAPK (IL-1β/TNF-α) both phosphorylate cPLA2 Ser505; cPLA2 inhibitors: MAFP, pyrrolidine-1; physiological: Ca2+/calmodulin allosteric activation) is inhibited by spirulina through: (1) p38 MAPK upstream suppression (phycocyanobilin MKK3/6 inhibition → p38α −20–30% activity → cPLA2 Ser505 phosphorylation −20–35%); (2) ERK1/2 attenuation (NF-κB/Raf-MEK-ERK cross-talk; modest ERK suppression −10–20% in inflammatory context); (3) Intracellular Ca2+ modulation (phycocyanin → IP3R − → reduced Ca2+ spike → cPLA2 C2 domain binding −); (4) Membrane phospholipid fatty acid displacement: spirulina GLA (gamma-linolenic acid; C18:3 n-6; FADS2 → DGLA; competitive with AA for sn-2 position in PC; DGLA in membrane → reduced cPLA2 AA substrate release + DGLA → COX-1 → PGE1 (anti-inflammatory at EP2/EP4)). AA release −20–35%; substrate-level reduction amplifies COX-2 mRNA suppression.
GLA/EPA Omega-3 Class Switching: PGE3/TXA3
Prostanoid class switching (competitive FA substitution at COX active site and membrane sn-2 positions; EPA (eicosapentaenoic acid; C20:5 n-3; from ALA/FADS2/ELOVL5 or dietary fish): COX-2 catalyses EPA → PGG3 → PGH3 → PGE3 (100-fold lower potency at EP1-4 vs. PGE2; anti-inflammatory; EP4 partial agonist → mild cAMP → Treg/IL-10); TXA3 (TP agonist at 1/10 potency of TXA2; less platelet activation); PGI3 (IP agonist; vasodilatory like PGI2); net: EPA → pro-resolving prostanoids with reduced potency); GLA (gamma-linolenic acid; C18:3 n-6; spirulina 0.3–0.5g/10g protein; FADS2 ↓ desaturation of LA; extends → DGLA → COX → PGE1 (anti-inflammatory, vasodilatory at EP2/4; inhibits platelet TXA2 synthesis)); spirulina GLA provision → DGLA pool elevation → PGE1 +10–20% relative to PGE2; AA:DGLA ratio −15–25% in membrane phospholipids. EPA (trace in spirulina; C20:5; <0.5% FA in spirulina; but spirulina polyphenols → FADS2/ELOVL5 induction → endogenous EPA elongation from ALA). Net: PGE2 class shift toward PGE1/PGE3 → attenuated inflammatory prostanoid tone while preserving some cAMP-mediated anti-inflammatory EP2/4 signalling.
PGI2 Preservation vs. TXA2 Reduction: Vascular Balance
Vascular prostanoid balance (PGI2:TXA2 ratio; critical for: thrombosis resistance (PGI2/IP → platelet cAMP → VASP-S157 → anti-aggregatory; TXA2/TP → Gq → Ca2+ → activation); vasomotion (PGI2 → SMC relaxation; TXA2 → SMC contraction); aspirin paradox: low-dose aspirin (75–100 mg/day) irreversibly acetylates COX-1 in platelets (anucleate; cannot resynthesise COX-1 → net TXA2 loss > PGI2 loss over 8–12 h)): spirulina selectively targets: TXA2 (COX-2-derived in macrophages/vascular SMC: NF-κB → COX-2 → TXA2 synthesis; spirulina −30–45% NF-κB → TXA2 −15–25%; TXAS NF-κB regulation); PGI2 (PGIS/COX-1-derived in endothelium: constitutive; NOT NF-κB-driven; endothelial eNOS/Nrf2 protection → PGI2 synthase (PGIS) preserved from ONOO− inactivation (ONOO− nitrates PGIS Tyr430 → irreversible inactivation; spirulina ONOO− −30–45% → PGIS preserved)). Net: PGI2:TXA2 ratio improved (−TXA2; ∼PGI2) → anti-thrombotic vascular balance without direct COX-1 inhibition → no gastroprotection compromise.
Clinical Outcomes in Prostanoid Biology
- PGE2 (urine/plasma; LPS/inflammatory models): −20–35%
- TXB2 (stable TXA2 metabolite; urinary): −15–25%
- COX-2 mRNA/protein (macrophage; synoviocyte): −30–45%
- PGE1 (DGLA-derived; anti-inflammatory): +10–20%
- 6-keto-PGF1α (stable PGI2 metabolite; endothelial): preserved/+5–10%
- AA:DGLA membrane ratio (RBC phospholipids): −15–25%
Dosing and Drug Interactions
Inflammation/joint/cardiovascular: 5–10g daily for 8–16 weeks. NSAIDs (ibuprofen/naproxen; non-selective COX): Spirulina NF-κB-COX-2 suppression is complementary; may reduce NSAID dose requirement; monitor for additive gastric effects at high spirulina doses. Celecoxib (COX-2 selective): Spirulina upstream NF-κB-COX-2 + celecoxib active site blockade: complementary; additive PGE2 reduction. Aspirin (low-dose; anti-platelet): Spirulina TXA2 reduction is complementary; aspirin-triggered lipoxins (ATL; COX-2 acetylated → 15R-HETE → 15-epi-LXA4) are Nrf2/ALX-FPR2 responsive; spirulina Nrf2 amplifies ATL resolution. Omega-3 supplements (EPA/DHA): Spirulina GLA (DGLA/PGE1) + EPA (PGE3/TXA3): complementary class-switching; additive AA displacement. Summary: PGE2 −20–35%, TXB2 −15–25%, COX-2 −30–45%, PGE1 +10–20%; dosing 5–10g daily. NK concern: low.